Medication evidence profile
Mebeverine
Clinical overview
Mebeverine has public medication-list entries in GABS 2018, KABS 2020 open validation supplement, and CALS 2022 Table 4. These are 3 separate source versions, each with its own evidence and definitions.
Source-specific scores
| Source | Score |
|---|---|
| JARS | Not listed |
| Yamada-ABS | Not listed |
| BAAS | Not listed |
| Swe-ABS | Not listed |
| GABS | 0 |
| KABS | 1 |
| CALS | 1 |
How to read this: 0 means the source explicitly assigned zero. “Not listed” means the source did not provide a score for this medication. Scores from different scales are not averaged.
How to interpret the evidence
3 of 7 public source versions contain an explicit medication-list entry for mebeverine.
The recorded values differ across the source rows for mebeverine. Scale methods, definitions, source eras, evidence types and identity handling can differ; the numbers alone do not establish the reason for this medication’s disagreement.
GABS 2018 explicitly records zero. Those recorded zeros remain different from a missing entry.
Source labels and provenance · 3 observations
- German Anticholinergic Burden Score 2018
Source label: Mebeverine. Published value: 0.
Source version: GABS-2018
Source location: 12877_2018_929_MOESM1_ESM.docx Table S3 row 203
Observation: GABS_2018_R0353; rating state: published_zero. - KABS 2019 scale - 2020 open validation supplement
Source label: Mebeverine. Published value: 1.
Source version: KABS-2020-validation-supplement
Source location: Additional file 1; category Drugs for gastrointestinal conditions and disorders; table row 67
Observation: KABS2020_SUPP_0351; rating state: published_validation_supplement_rating. - CALS 2022 - primary final Table 4
Source label: Mebeverine. Published value: 1.
Source version: CALS-2022-primary-table4
Source location: Table 4; literal capture row 94; displayed table row 14; displayed column 3
Observation: CALS2022_T4_0094; rating state: published_final_table_rating.
What this page does not establish
- No medication-list entry is available here from JARS 2025, Yamada-ABS 2023, BAAS 2019, and Swe-ABS 2023. These gaps remain “Not listed”; no score is inferred from another source or from class membership.
- No route inference unless present in the source label.
- These source records do not estimate an individual’s probability of harm or establish whether to start, stop or change a medication. Ordinal source scores are not averaged into a UnifiedACB score.
References
- Kiesel EK, Hopf YM, Drey M. An anticholinergic burden score for German prescribers: score development. BMC Geriatr. 2018;18(1):239. doi:10.1186/s12877-018-0929-6. Open source
- Suh Y, Ah YM, Han E, et al. Dose response relationship of cumulative anticholinergic exposure with incident dementia: validation study of Korean anticholinergic burden scale. BMC Geriatr. 2020;20(1):265. doi:10.1186/s12877-020-01671-z. Open source
- Ramos H, Moreno L, Pérez-Tur J, Cháfer-Pericás C, García-Lluch G, Pardo J. CRIDECO Anticholinergic Load Scale: an updated anticholinergic burden scale. Comparison with the ACB Scale in Spanish individuals with subjective memory complaints. J Pers Med. 2022;12(2):207. doi:10.3390/jpm12020207. Open source
Ask a follow-up
Go to your medication comparison · How UnifiedACB handles disagreement
Ask about this medication
Medication context: Mebeverine
Ask about this medication